论文部分内容阅读
目的:探讨亚甲基二磷酸盐(99TC-MDP，云克)联合氯化锶(n 89SrCln 2)治疗多发性骨转移癌骨痛的临床疗效。n 方法:回顾性分析大同同煤集团总医院2014年8月至2019年7月收治的多发性骨转移癌骨痛患者95例的临床资料，依据治疗方法不同分为三组，云克组37例采用单独云克治疗、n 89SrCln 2组29例采用单独n 89SrCln 2治疗，联合组29例采用云克联合n 89SrCln 2治疗，三组均治疗5 d，每月为1疗程。比较三组临床疗效、止痛时间及不良反应。n 结果:治疗后，云克组、n 89SrCln 2组、联合组患者疼痛缓解率分别为67.6%(25/37)、69.0%(20/29)、79.3%(23/29)，联合组疼痛缓解率高于云克组(χn 2＝4.25，n P<0.05)；联合组骨转移灶有效率为41.4%(12/29)，高于云克组的0.0%(0/37)、n 89SrCln 2组的17.2%(5/29)，差异均有统计学意义(χn 2＝13.09、10.54，均n P<0.01)。三组均未发现严重不良反应。n 结论:云克联合n 89SrCln 2治疗骨转移癌，明显优于单独n 89SrCln 2及单独云克治疗，且安全。n “,”Objective:To investigate the clinical efficacy of Yunke(99TC-MDP) combined with strontium 89SrCl2 in the treatment of bone pain in patients with multiple bone metastases.Methods:The clinical data of 95 patients with multiple bone metastases admitted to the General Hospital of Datong Coal Group from August 2014 to July 2019 were retrospectively analyzed.According to the different treatment methods, they were divided into three groups: 37 patients in Yunke group were treated with Yunke alone, 29 patients in 89SrCl2 group were treated with 89SrCl2 alone, 29 patients in combination group were treated with Yunke combined with 89SrCl2.All patients were treated for 5 days, with a course of treatment per month.The clinical efficacy, analgesic time and adverse reactions of the three groups were compared.Results:After treatment, the pain relief rates of the Yunke group, the 89SrCl2 group and the combination group were 67.6%(25/37), 69.0%(20/29) and 79.3%(23/29), respectively.The pain relief rate of the combined group was higher than that of the Yunke group(χn 2=4.25, n P<0.05). The effective rate of bone metastases in the combined group was 41.4%(12/29), which was higher than that in the Yunke group[0.0%(0/37)], the 89SrCl2 group[17.2%(5/29)], the differences were statistically significant(χn 2=13.09, 10.54, all n P<0.01). No serious adverse reactions were found in the three groups.n Conclusion:Yunke combined with 89SrCl2 is superior to 89SrCl2 alone, and it is safe in the treatment of bone metastases.